Literature DB >> 18973843

Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update.

T Poynard1, M Muntenau, R Morra, Y Ngo, F Imbert-Bismut, D Thabut, D Messous, J Massard, P Lebray, J Moussalli, Y Benhamou, V Ratziu.   

Abstract

This review summarizes the methodological aspects of the interpretation of non-invasive biomarkers in liver fibrosis. A scoring system has been updated to better compare the quality of fibrosis biomarkers. Several methodological issues are related to the classical methodology using biopsy, as this is considered the gold standard. However, from evidence-based data, it appears that the methodology needs to change to prevent flawed conclusions among key opinion leaders as well as in obsolete guidelines. As waiting for the perfect biomarker for the diagnosis of advanced fibrosis to come along is probably a waste of time, in the meantime, methods can be improved. The main proposals for improving the methodology are, to take into account the spectrum bias, to assess accuracy between adjacent stages, to compare biomarkers in the same patient, to assess the cause of failure among discordant cases and to use specific statistical methods adapted for imperfect gold standards.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973843     DOI: 10.1016/S0399-8320(08)73990-3

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  13 in total

1.  A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C.

Authors:  G Shiha; S Seif; A Eldesoky; M Elbasiony; R Soliman; A Metwally; K Zalata; N Mikhail
Journal:  Hepatol Int       Date:  2017-04-19       Impact factor: 6.047

2.  Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection.

Authors:  Shawky Abdelhamid Fouad; Serag Esmat; Dalia Omran; Laila Rashid; Mohamed H Kobaisi
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 3.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Authors:  Natalie J Torok; Jonathan A Dranoff; Detlef Schuppan; Scott L Friedman
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

4.  Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

Authors:  Thierry Poynard; Yen Ngo; Mona Munteanu; Dominique Thabut; Vlad Ratziu
Journal:  Curr Hepat Rep       Date:  2011-03-01

5.  Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B.

Authors:  Sheng-di Wu; Yan-Jun Ni; Li-Li Liu; Hai Li; Lun-Gen Lu; Ji-Yao Wang
Journal:  Hepatol Int       Date:  2011-12-10       Impact factor: 6.047

6.  Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

Authors:  Thierry Poynard; Pascal Lebray; Patrick Ingiliz; Anne Varaut; Brigitte Varsat; Yen Ngo; Pascal Norha; Mona Munteanu; Fabienne Drane; Djamila Messous; Françoise Imbert Bismut; Jean Pierre Carrau; Julien Massard; Vlad Ratziu; Jean Pierre Giordanella
Journal:  BMC Gastroenterol       Date:  2010-04-22       Impact factor: 3.067

7.  Assessment of liver fibrosis: noninvasive means.

Authors:  Thierry Poynard; Rachel Morra; Patrick Ingiliz; Françoise Imbert-Bismut; Dominique Thabut; Djamila Messous; Mona Munteanu; Julien Massard; Yves Benhamou; Vlad Ratziu
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

8.  Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study.

Authors:  Sheng-Di Wu; Ji-Yao Wang; Lei Li
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

9.  Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

Authors:  Thierry Poynard; Mona Munteanu; Olivier Deckmyn; Yen Ngo; Fabienne Drane; Djamila Messous; Jean Marie Castille; Chantal Housset; Vlad Ratziu; Françoise Imbert-Bismut
Journal:  BMC Gastroenterol       Date:  2011-04-14       Impact factor: 3.067

10.  Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

Authors:  Thierry Poynard; Guillaume Lassailly; Emmanuel Diaz; Karine Clement; Robert Caïazzo; Joan Tordjman; Mona Munteanu; Hugo Perazzo; Bernard Demol; Robert Callafe; François Pattou; Frederic Charlotte; Pierre Bedossa; Philippe Mathurin; Vlad Ratziu
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.